Skip to main content
. 2019 Jul 29;37(26):2349–2359. doi: 10.1200/JCO.19.00177

FIG A2.

FIG A2.

Participant flow diagram. Patients with high-risk solid tumors were eligible for enrollment. Eighteen patients were enrolled and 15 were infused with tumor-associated antigen cytotoxic T cells (TAA-T) at the time of manuscript. One patient was removed from treatment before day 45 as a result of disease progression. Fourteen patients remained evaluable for toxicity.